Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Glioblastoma, IDH-wildtypeMetforminMalignancies
Interventions
DRUG

Metformin

"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."

Trial Locations (1)

Unknown

RECRUITING

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan

All Listed Sponsors
lead

University of Milano Bicocca

OTHER